These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25156643)

  • 21. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
    Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
    Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Rusinek H; Li J; Tsui W; Saint Louis LA; Clark CM; Tarshish C; Li Y; Lair L; Javier E; Rich K; Lesbre P; Mosconi L; Reisberg B; Sadowski M; DeBernadis JF; Kerkman DJ; Hampel H; Wahlund LO; Davies P
    Neurobiol Aging; 2006 Mar; 27(3):394-401. PubMed ID: 16125823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited.
    Boelaarts L; de Jonghe JFM; Scheltens P
    Dement Geriatr Cogn Disord; 2020; 49(1):2-7. PubMed ID: 32224618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idiopathic normal-pressure hydrocephalus, cerebrospinal fluid biomarkers, and the cerebrospinal fluid tap test.
    Kang K; Ko PW; Jin M; Suk K; Lee HW
    J Clin Neurosci; 2014 Aug; 21(8):1398-403. PubMed ID: 24836892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of CSF markers in the early diagnosis of Alzheimer's disease].
    Vos SJ; Visser PJ; Verhey FR
    Tijdschr Psychiatr; 2011; 53(9):647-53. PubMed ID: 21898322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effect of bilingualism on Alzheimer's disease CSF biomarkers and cognition.
    Estanga A; Ecay-Torres M; Ibañez A; Izagirre A; Villanua J; Garcia-Sebastian M; Iglesias Gaspar MT; Otaegui-Arrazola A; Iriondo A; Clerigue M; Martinez-Lage P
    Neurobiol Aging; 2017 Feb; 50():144-151. PubMed ID: 27916386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity.
    Ganzer S; Arlt S; Schoder V; Buhmann C; Mandelkow EM; Finckh U; Beisiegel U; Naber D; Müller-Thomsen T
    J Neural Transm (Vienna); 2003 Oct; 110(10):1149-60. PubMed ID: 14523627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
    Stomrud E; Hansson O; Zetterberg H; Blennow K; Minthon L; Londos E
    Arch Neurol; 2010 Feb; 67(2):217-23. PubMed ID: 20142530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid beta 1-42 in cerebrospinal fluid is associated with cognitive plasticity.
    Uttner I; Schurig N; von Arnim CA; Lange-Asschenfeldt C; Brettschneider J; Riepe MW; Tumani H
    Psychiatry Res; 2011 Nov; 190(1):132-6. PubMed ID: 21620485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Alzheimer's disease cerebro-spinal fluid biomarkers: A clinical research tool sometimes useful in daily clinical practice of memory clinics for the diagnosis of complex cases].
    Magnin E; Dumurgier J; Bouaziz-Amar E; Bombois S; Wallon D; Gabelle A; Lehmann S; Blanc F; Bousiges O; Hannequin D; Jung B; Miguet-Alfonsi C; Quillard M; Pasquier F; Peoc'h K; Laplanche JL; Hugon J; Paquet C;
    Rev Med Interne; 2017 Apr; 38(4):250-255. PubMed ID: 27890382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum.
    Solé-Padullés C; Lladó A; Bartrés-Faz D; Fortea J; Sánchez-Valle R; Bosch B; Antonell A; Molinuevo JL; Rami L
    Psychiatry Res; 2011 Jun; 192(3):140-6. PubMed ID: 21546220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid biomarkers in Progranulin mutations carriers.
    Carecchio M; Fenoglio C; Cortini F; Comi C; Benussi L; Ghidoni R; Borroni B; De Riz M; Serpente M; Cantoni C; Franceschi M; Albertini V; Monaco F; Rainero I; Binetti G; Padovani A; Bresolin N; Scarpini E; Galimberti D
    J Alzheimers Dis; 2011; 27(4):781-90. PubMed ID: 21891865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
    Ivanoiu A; Sindic CJ
    Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are CSF biomarkers ready for prime time as diagnostics for Alzheimer disease? Interview by Rebecca Voelker.
    Holtzman DM
    JAMA; 2010 Nov; 304(17):1887. PubMed ID: 21045090
    [No Abstract]   [Full Text] [Related]  

  • 39. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index].
    Molinuevo JL; Gispert JD; Pujol J; Rojas S; Lladó A; Balasa M; Antonell A; Sánchez-Valle R; Rami L
    Rev Neurol; 2012 May; 54(9):513-22. PubMed ID: 22532214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.